EX-4.4



 Exhibit 4.4 

THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE
SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. 

Trilypsa, Inc. 
 WARRANT
TO PURCHASE SERIES A PREFERRED STOCK 
  

			
	No. PCW-1	 	August 9, 2013

 Void After August 9, 2020 

THIS CERTIFIES THAT, for value received, SIBLING CO-INVESTMENT LLC, or its assigns (the
“Holder”), is entitled to subscribe for and purchase at the Exercise Price (defined below) from TRILYPSA, INC., a Delaware corporation, with its principal office at 400 East Jamie Court, Suite 201, South San Francisco, California,
94080 (the “Company”), shares of the equity securities of the Company of the same class and series as are issued and sold by the Company pursuant to the Qualified Financing (as defined below) (the “Series A Preferred Stock”) as
set forth below and subject to adjustment provided herein. 
 This Warrant is being issued pursuant to the terms of the Note and Warrant
Purchase Agreement, dated August 9, 2013, by and among the Company and the Holder (the “Note and Warrant Purchase Agreement”). Unless indicated otherwise, the number of shares of Series A Preferred Stock that Holder may purchase by
exercising this warrant is equal to the quotient of (A) seventeen percent (17%) multiplied by $500,000.00 divided by (B) the per share price of the Series A Preferred Stock sold in the Qualified Financing. 

1.    Definitions. As used herein, the following terms shall have the following respective meanings: 

(a)    “Exercise Period” shall mean the period commencing with the date hereof and ending seven
(7) years later, unless sooner terminated as provided below. 
 (b)    “Exercise Price” shall mean
the share price of the Series A Preferred Stock sold in the Qualified Financing, subject to adjustment pursuant to Section 5 below. 

(c)    “Exercise Shares” shall mean the shares of the Company’s Series A Preferred Stock issuable
upon exercise of this Warrant, subject to adjustment pursuant to the terms herein, including but not limited to adjustment pursuant to Section 5 below. 

(d)    “Note” shall mean the Convertible Promissory Note issued by the Company pursuant to the Note and
Warrant Purchase Agreement, as amended from time to time. 

  
 1 


 CONFIDENTIAL 








 1.2    “Qualified Financing” shall mean the sale and
issuance of the Company’s Series A Preferred Stock occurring prior to May 9, 2014 (the “Demand Date”) and following the date of the Note (the “Seed Closing Date”) which results in aggregate gross proceeds of at least
$8,000,000.00 (not including the aggregate principal amount and all accrued interest of the Note) (or such other lesser amount as is approved by at least seventy-five percent (75%) of the Company’s board of directors) to the Company from all
sales and issuances of its Series A Preferred Stock in financings after the Seed Closing Date. 

2.    Exercise of Warrant. The rights represented by this Warrant may be exercised in whole or in part at
any time during the Exercise Period, by delivery of the following to the Company at its address set forth above (or at such other address as it may designate by notice in writing to the Holder): 

(a)    An executed Notice of Exercise in the form attached hereto; 

(b)    Payment of the Exercise Price either (i) in cash or by check, or (ii) by cancellation of
indebtedness; and 
 (c)    This Warrant. 

Upon the exercise of the rights represented by this Warrant, a certificate or certificates for the Exercise Shares so purchased, registered in
the name of the Holder or persons affiliated with the Holder, if the Holder so designates, shall be issued and delivered to the Holder within a reasonable time after the rights represented by this Warrant shall have been so exercised. 

The person in whose name any certificate or certificates for Exercise Shares are to be issued upon exercise of this Warrant shall be deemed to
have become the holder of record of such shares on the date on which this Warrant was surrendered and payment of the Exercise Price was made, irrespective of the date of delivery of such certificate or certificates, except that, if the date of such
surrender and payment is a date when the stock transfer books of the Company are closed, such person shall be deemed to have become the holder of such shares at the close of business on the next succeeding date on which the stock transfer books are
open. 
 2.1    Net Exercise. Notwithstanding any provisions herein to the contrary, if the fair market
value of one share of the Company’s Series A Preferred Stock is greater than the Exercise Price (at the date of calculation as set forth below), in lieu of exercising this Warrant by payment of cash, the Holder may elect to receive shares equal
to the value (as determined below) of this Warrant (or the portion thereof being canceled) by surrender of this Warrant at the principal office of the Company together with the properly endorsed Notice of Exercise in which event the Company shall
issue to the Holder a number of shares of Series A Preferred Stock computed using the following formula: 
 X = Y (A-B) 
             A 

Where X = the number of shares of Series A Preferred Stock to be issued to the 

Holder 

  
 2 


 CONFIDENTIAL 









	 	Y =	the number of shares of Series A Preferred Stock purchasable under the Warrant or, if only a portion of the Warrant is being exercised, the portion of the Warrant being canceled (at the date of such calculation)


  

	 	A =	the fair market value of one share of the Company’s Series A Preferred Stock (at the date of such calculation) 

  

	 	B =	Exercise Price (as adjusted to the date of such calculation) 

 For purposes of the above
calculation, the fair market value of one share of Series A Preferred Stock shall be determined by the Company’s board of directors; provided, however, that in the event that this Warrant is exercised pursuant to this Section 2.1 in
connection with the Company’s initial public offering of its Common Stock, the fair market value per share shall be the product of (i) the per share offering price to the public of the Company’s initial public offering, and
(ii) the number of shares of Common Stock into which each share of Series A Preferred Stock is convertible at the time of such exercise. 

3.    Covenants of the Company. 

3.1    Covenants as to Exercise Shares. The Company covenants and agrees that all Exercise Shares that may
be issued upon the exercise of the rights represented by this Warrant will, upon issuance, be validly issued and outstanding, fully paid and nonassessable, and free from all taxes, liens and charges with respect to the issuance thereof. The Company
further covenants and agrees that the Company will at all times during the Exercise Period, have authorized and reserved, free from preemptive rights, a sufficient number of shares of its Preferred Stock to provide for the exercise of the rights
represented by this Warrant. If at any time during the Exercise Period the number of authorized but unissued shares of Preferred Stock shall not be sufficient to permit exercise of this Warrant, the Company will take such corporate action as may, in
the opinion of its counsel, be necessary to increase its authorized but unissued shares of Preferred Stock to such number of shares as shall be sufficient for such purposes. 

3.2    No Impairment. Except and to the extent as waived or consented to by the Holder, the Company will
not, by amendment of its Certificate of Incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or
performance of any of the terms to be observed or performed hereunder by the Company, but will at all times in good faith assist in the carrying out of all the provisions of this Warrant and in the taking of all such action as may be necessary or
appropriate in order to protect the exercise rights of the Holder against impairment. 
 3.3    Notices of
Record Date. In the event of any taking by the Company of a record of the holders of any class of securities for the purpose of determining the holders thereof who are entitled to receive any dividend (other than a cash dividend which is the
same as cash dividends paid in previous quarters) or other distribution, the Company shall mail to the Holder, at least ten (10) days prior to the date specified herein, a notice specifying the date on which any such record is to be taken for
the purpose of such dividend or distribution. 

  
 3 


 CONFIDENTIAL 








 4.    Representations of Holder. 

4.1    Acquisition of Warrant for Personal Account and Accredited Investor Status. 

(a)    The Holder represents and warrants that it is acquiring the Warrant and the Exercise Shares solely for its
account for investment and not with a view to or for sale or distribution of said Warrant or Exercise Shares or any part thereof. The Holder also represents that the entire legal and beneficial interests of the Warrant and Exercise Shares the Holder
is acquiring is being acquired for, and will be held for, its account only. 
 (b)    The Holder is an
“accredited investor” as such term is defined in Rule 501 under the Act (as defined below). 

4.2    Securities Are Not Registered. 

(a)    The Holder understands that the Warrant and the Exercise Shares have not been registered under the Act on
the basis that no distribution or public offering of the stock of the Company is to be effected. The Holder realizes that the basis for the exemption may not be present if, notwithstanding its representations, the Holder has a present intention of
acquiring the securities for a fixed or determinable period in the future, selling (in connection with a distribution or otherwise), granting any participation in, or otherwise distributing the securities. The Holder has no such present intention.

 (b)    The Holder recognizes that the Warrant and the Exercise Shares must be held indefinitely unless they
are subsequently registered under the Act or an exemption from such registration is available. The Holder recognizes that the Company has no obligation to register the Warrant or the Exercise Shares of the Company, or to comply with any exemption
from such registration. 
 (c)    The Holder is aware that neither the Warrant nor the Exercise Shares may be
sold pursuant to Rule 144 adopted under the Act unless certain conditions are met, including, among other things, the existence of a public market for the shares, the availability of certain current public information about the Company, the resale
following the required holding period under Rule 144 and the number of shares being sold during any three month period not exceeding specified limitations. Holder is aware that the conditions for resale set forth in Rule 144 have not been satisfied
and that the Company presently has no plans to satisfy these conditions in the foreseeable future. 

4.3    Disposition of Warrant and Exercise Shares. 

(a)    The Holder further agrees not to make any disposition of all or any part of the Warrant or Exercise Shares
in any event unless and until: 
 (i)    The Company shall have received a letter secured by the Holder from the
Securities and Exchange Commission stating that no action will be recommended to the Commission with respect to the proposed disposition; 

  
 4 


 CONFIDENTIAL 








 (ii)    There is then in effect a registration statement under the
Act covering such proposed disposition and such disposition is made in accordance with said registration statement; or 

(iii)    The Holder shall have notified the Company of the proposed disposition and shall have furnished the
Company with a detailed statement of the circumstances surrounding the proposed disposition, and if reasonably requested by the Company, the Holder shall have furnished the Company with an opinion of counsel, reasonably satisfactory to the Company,
for the Holder to the effect that such disposition will not require registration of such Warrant or Exercise Shares under the Act or any applicable state securities laws. 

(b)    The Holder understands and agrees that all certificates evidencing the shares to be issued to the Holder
may bear the following legend: 
 THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS
NOT REQUIRED. 
 5.    Adjustment of Exercise Price. In the event of changes in the outstanding Series A
Preferred Stock of the Company by reason of stock dividends, split-ups, recapitalizations, reclassifications, combinations or exchanges of shares, separations, reorganizations, liquidations, or the like, the
number and class of shares available under the Warrant in the aggregate and the Exercise Price shall be correspondingly adjusted to give the Holder of the Warrant, on exercise for the same aggregate Exercise Price, the total number, class, and kind
of shares as the Holder would have owned had the Warrant been exercised prior to the event and had the Holder continued to hold such shares until after the event requiring adjustment; provided, however, that such adjustment shall not be made with
respect to, and this Warrant shall terminate if not exercised prior to, the events set forth in Section 7 below. The form of this Warrant need not be changed because of any adjustment in the number of Exercise Shares subject to this Warrant.

 6.    Fractional Shares. No fractional shares shall be issued upon the exercise of this Warrant as a
consequence of any adjustment pursuant hereto. All Exercise Shares (including fractions) issuable upon exercise of this Warrant may be aggregated for purposes of determining whether the exercise would result in the issuance of any fractional share.
If, after aggregation, the exercise would result in the issuance of a fractional share, the Company shall, in lieu of issuance of any fractional share, pay the Holder otherwise entitled to such fraction a sum in cash equal to the product resulting
from multiplying the then current fair market value of an Exercise Share by such fraction. 
 7.    Early
Termination. 
 7.1    In the event of, at any time during the Exercise Period, an initial public offering of
securities of the Company registered under the Act, or any capital reorganization, or 

  
 5 


 CONFIDENTIAL 








 
any reclassification of the capital stock of the Company (other than a change in par value or from par value to no par value or no par value to par value or as a result of a stock dividend or
subdivision, split-up or combination of shares), or the consolidation or merger of the Company with or into another corporation (other than a merger solely to effect a reincorporation of the Company into
another state), or the sale or other disposition of all or substantially all the properties and assets of the Company in its entirety to any other person, the Company shall provide to the Holder twenty (20) days advance written notice of such
public offering, reorganization, reclassification, consolidation, merger or sale or other disposition of the Company’s assets, and this Warrant shall terminate unless exercised prior to the date such public offering is closed or the occurrence
of such reorganization, reclassification, consolidation, merger or sale or other disposition of the Company’s assets. 

7.2    In the event a Qualified Financing does not occur on or before May 9, 2014, this Warrant shall
automatically terminate effective as of such date. 
 8.    Market
Stand-Off Agreement. Holder hereby agrees that Holder shall not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction
with the same economic effect as a sale, any shares of Common Stock (or other securities) of the Company held by Holder (other than those included in the registration) (i) during the 180-day period
following the effective date of the initial public offering (or such longer period as the underwriters or the Company shall request in order to facilitate compliance with NASD Rule 2711 or NYSE Member Rule 472 or any successor or similar rule or
regulation), and (ii) during the 90-day period following the effective date of a registration statement of the Company filed under the Act (or such longer period as the underwriters or the Company shall
request in order to facilitate compliance with NASD Rule 2711 or NYSE Member Rule 472 or any successor or similar rule or regulation); provided, that, with respect to (i) and (ii) above, all officers and directors of the Company are bound by
and have entered into similar agreements. Holder agrees to execute and deliver such other agreements as may be reasonably requested by the Company or the managing underwriters that are consistent with the foregoing or that are necessary to give
further effect thereto. In addition, if requested by the Company or the representative of the underwriters of Common Stock (or other securities) of the Company, Holder shall provide, within ten (10) days of such request, such information as may
be required by the Company or such representative in connection with the completion of any public offering of the Company’s securities pursuant to a registration statement filed under the Act. The obligations described in this Section 8
shall not apply to a registration relating solely to employee benefit plans on Form S-1 or Form S-8 or similar forms that may be promulgated in the future, or a
registration relating solely to a transaction on Form S-4 or similar forms that may be promulgated in the future. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions
with respect to such Common Stock (or other securities) until the end of such period. Holder agrees that any transferee of any of the Common Stock (or other securities) of the Company held by Holder shall be bound by this Section 8. The
underwriters of the Company’s stock are intended third party beneficiaries of this Section 8 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. 

9.    No Stockholder Rights. This Warrant in and of itself shall not entitle the Holder to any voting rights
or other rights as a stockholder of the Company. 

  
 6 


 CONFIDENTIAL 








 10.    Transfer of Warrant. Subject to applicable laws and the
restriction on transfer set forth on the first page of this Warrant, this Warrant and all rights hereunder are transferable, by the Holder in person or by duly authorized attorney, upon delivery of this Warrant and the form of assignment attached
hereto to any transferee designated by Holder. The transferee shall sign an investment letter in form and substance satisfactory to the Company. 

11.    Lost, Stolen, Mutilated or Destroyed Warrant. If this Warrant is lost, stolen, mutilated or
destroyed, the Company may, on such terms as to indemnity or otherwise as it may reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender thereof), issue a new Warrant of like denomination and tenor as the Warrant so
lost, stolen, mutilated or destroyed. Any such new Warrant shall constitute an original contractual obligation of the Company, whether or not the allegedly lost, stolen, mutilated or destroyed Warrant shall be at any time enforceable by anyone. 

12.    Waiver and Amendment. Any term of this Warrant may be amended or waived with the written consent of
the Company and Holder, as provided in the Note and Warrant Purchase Agreement. 
 13.    Notices, etc.
All notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed telex, facsimile or electronic mail if sent during
normal business hours of the recipient, if not, then on the next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a
nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be sent to the Company at the address listed on the signature page and to Holder at 18313 Calle La Serra, Rancho
Santa Fe, California, 92091 or at such other address as the Company or Holder may designate by ten (10) days advance written notice to the other parties hereto. 

14.    Acceptance. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all
of the terms and conditions contained herein. 
 15.    Governing Law. This Warrant and all rights,
obligations and liabilities hereunder shall be governed by the laws of the State of California without giving effect to conflict of laws principles. 

16.    Counterparts. This Warrant may be executed in one or more counterparts, each of which shall be deemed
an original, but all of which together shall constitute one and the same instrument. 
 [REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]


  
 7 


 CONFIDENTIAL 








 IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its duly
authorized officer as of the date first written above. 
  

			
	TRILYPSA, INC.
		
	By:	 	/s/ Gerrit Klaerner
		 	Gerrit Klaerner
		 	Chief Executive Officer


 
			
		
	Address:	 	400 East Jamie Court, Suite 201
		 	South San Francisco, CA 94080


  

	
	 AGREED TO AND ACCEPTED:

	
	SIBLING CO-INVESTMENT LLC
	
	/s/ Sandra I. Coufal, M.D.
	 Signature

	
	Sandra I. Coufal, M.D.
	 Name (please print)

	
	Manager
	 Title (if applicable)


 Signature Page to Warrant 







 NOTICE OF EXERCISE 

TO: TRILYPSA, INC. 

(1)    ☐    The undersigned hereby elects to purchase
                     shares of the Series A Preferred Stock of TRILYPSA, INC. (the “Company”) pursuant to the terms of the
attached Warrant, and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any. 

         ☐    The undersigned hereby elects to purchase shares of the
Series A Preferred Stock of TRILYPSA, INC. (the “Company”) pursuant to the terms of the net exercise provisions set forth in Section 2.1 of the attached Warrant, and shall tender payment of all applicable transfer taxes, if
any. 
 (2)    Please issue a certificate or certificates representing said shares of Series A Preferred Stock in
the name of the undersigned or in such other name as is specified below: 
  

 
 (Name) 

 
  

 
  

(Address) 

(3)    The undersigned represents that (i) the aforesaid shares of Series A Preferred Stock are being acquired
for the account of the undersigned for investment and not with a view to, or for resale in connection with, the distribution thereof and that the undersigned has no present intention of distributing or reselling such shares; (ii) the
undersigned is aware of the Company’s business affairs and financial condition and has acquired sufficient information about the Company to reach an informed and knowledgeable decision regarding its investment in the Company; (iii) the
undersigned is experienced in making investments of this type and has such knowledge and background in financial and business matters that the undersigned is capable of evaluating the merits and risks of this investment and protecting the
undersigned’s own interests; (iv) the undersigned is an “accredited investor” as defined in Rule 501 under the Securities Act; (v) the undersigned understands that the shares of Series A Preferred Stock issuable upon
exercise of this Warrant have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), by reason of a specific exemption from the registration provisions of the Securities Act, which exemption depends upon,
among other things, the bona fide nature of the investment intent as expressed herein, and, because such securities have not been registered under the Securities Act, they must be held indefinitely unless subsequently registered under the Securities
Act or an exemption from such registration is available; (vi) the undersigned is aware that the aforesaid shares of Series A Preferred Stock may not be sold pursuant to Rule 144 adopted under the Securities Act unless certain conditions are met
and until the undersigned has held the shares for the number of years prescribed by Rule 144, that among the conditions for use of the Rule is the availability of current information to the public about the Company and the








 
Company has not made such information available and has no present plans to do so; and (vii) the undersigned agrees not to make any disposition of all or any part of the aforesaid shares of
Series A Preferred Stock unless and until there is then in effect a registration statement under the Securities Act covering such proposed disposition and such disposition is made in accordance with said registration statement, or the undersigned
has provided the Company with an opinion of counsel satisfactory to the Company, stating that such registration is not required. 
  

					
	   
	 		 	   

	(Date)	 		 	(Signature)
			
	  
	 		 	   

		 		 	(Print name)








 ASSIGNMENT FORM 

(To assign the foregoing Warrant, execute this form and supply 

required information. Do not use this form to purchase shares.) 

FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to 

 

			
	 Name:
	  	 
		  	(Please Print)

  

			
	 Address:
	  	 
		  	(Please Print)

 Dated:
                        , 20     

Holder’s 
 Signature:
                                         
                                         
           
 Holder’s 

Address:
                                         
                                         
             
 NOTE: The signature to this Assignment Form must correspond with the
name as it appears on the face of the Warrant, without alteration or enlargement or any change whatever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the
foregoing Warrant.